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AbstrAct
Prostaglandin E-2 (PGE-2) promotes tumor angiogenesis via paracrine secretion 
of pro-angiogenic growth factors, such as vascular endothelial growth factor (VEGF). 
Since miRNAs  regulate several cell processes, including angiogenesis, we sought 
to determine whether they would influence PGE-2-induced VEGF. We compared 
DU145 and PC3 prostate cancer cells bearing the mPGES-1 enzyme (mPGES-1+/+) and 
producing PGE-2, with those in which the enzyme was silenced or deleted (mPGES-1-/-). 
We demonstrated that mPGES-1/PGE-2 signaling decreased Dicer expression and 
miRNA biogenesis. Genome-wide sequencing of miRNAs revealed that miR-15a and 
miR-186, associated with expression of VEGF and hypoxia inducible factor-1α (HIF-
1α), were down-regulated in mPGES-1+/+ cells. As a consequence, mPGES-1+/+ tumor 
cells expressed high levels of VEGF and HIF-1α, induced  endothelial cells activation 
and formed highly vascularized tumors. Mir-186 mimic inhibited VEGF expression in 
mPGES-1+/+ tumor xenografts and reduced tumor growth. In human prostate cancer 
specimens, mPGES-1 was over-expressed in tumors with high Gleason score, elevated 
expression of VEGF and HIF-1α, high microvessel density and decreased expression 
of Dicer, miR15a and miR-186. Thus, clear evidence for regulating miRNA processing 
and VEGF output by intrinsic PGE-2 production provides a means to distinguish 
between aggressive and indolent prostate tumors and suggests a potential target 
for controlling tumor progression.
IntroductIon 
Like other solid tumors, prostate cancer promotes 
angiogenesis to support its survival and inherent propensity 
to colonize other tissues. Many reports have described 
the close relationship between tumor and endothelium, 
as well as documenting the existence of a pool of tumor-
derived angiocrine factors that induce vessel development, 
including vascular endothelial growth factor (VEGFA) [1]. 
Similar principles govern angiogenesis in prostate cancer, 
as VEGF and other factors secreted by tumors have been 
reported to promote neovascularization [2, 3]. Although, 
angiogenesis is often regarded as a distinguishing feature of 
aggressive versus indolent phenotype [4], its relevance for 
prostate cancer progression has been questioned on the basis 
of lack of efficacy of antiangiogenic agents [5, 6]. The robust 
tumorigenic drive of DU145 prostate cancer cells has been 
associated with constitutive over-expression of microsomal 
prostaglandin E synthase-1 (mPGES-1) and higher output 
of PGE-2 [7], which, in turn, impinges on several pro-
tumorigenic pathways such as EGFR and Wnt [8–13].
Another layer of regulation for prostate cancer 
progression is the recently recognized role of miRNA 
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expression, which appears to control several key processes 
of tumor biology [14]. In this work we sought to determine 
whether mPGES-1/PGE-2 signaling influence miRNA 
expression and whether these miRNAs might be involved 
in VEGF expression in vitro and tumor angiogenesis in 
vivo. By comparing DU145 and PC3 prostate cancer 
models bearing the mPGES-1 functional enzyme 
(transfected with scrambled control shRNA or CRISPR/
Cas9 control, i.e. mPGES-1+/+ cells) with those in which 
the enzyme is silenced or deleted (knocked down or 
knocked out, i.e. mPGES-1-/- cells), we provide evidence 
that tumor-derived PGE-2 represses miRNA biogenesis, 
inhibiting Dicer expression by an autocrine mechanism. 
Genome-wide sequencing of miRNAs in mPGES-1+/+ 
compared to mPGES-1-/- cells revealed repression of miR-
15a and miR-186, both associated with VEGF expression. 
Immunohistochemical analysis of mPGES-1 expression 
revealed that the enzyme was strongly expressed in human 
tumors with high Gleason score, VEGF, and HIF-1α as 
well as with microvessel density, and low expression of 
Dicer, miR15a and miR-186. Thus it appears that 
mPGES-1/PGE-2 signaling increases VEGF expression 
in prostate cancer by inhibiting the miRNA processing.
results
mPGes-1 expression is associated with tumor growth, 
VeGF expression and vessel density
We investigated how prostate cancer cell-derived 
PGE-2 controls VEGF expression and tumor angiogenesis 
in DU145 and PC3 cells. VEGF expression/levels were 
up-regulated in mPGES-1+/+ compared to mPGES-1-/- 
cells, as measured by QPCR western blot and ELISA 
(Figure 1A, 1B, 1C). When mPGES-1 was silenced, 
VEGF expression decreased. MF63 (10 µM), a reversible 
mPGES-1 inhibitor, significantly decreased VEGF 
expression in mPGES-1+/+ cells with maximum effect 
at 8–18 h (Figure 1D), while exogenous PGE-2 (1 µM) 
increased VEGF release and expression in mPGES-1-/- 
cells time-dependently (Figure 1B, 1E).
In mouse xenograft of DU145 and PC3, mPGES-1+/+ 
tumor size was significantly higher than mPGES-1-/- tumor 
size (Supplementary Figure S1A, S1B). mPGES-1+/+ tumors 
displayed higher vessel density and increased luminal size 
(Figure 2A left and right graph, respectively). Hoechst 
33342 diffusion in mPGES-1+/+ tumors exhibited an 
intense and diffused perfusion, indicative of an abnormal 
vasculature (Figure 2B, panel A), while mPGES-1-/- tumors 
had a reduced vascular perfusion around the vessels (Figure 
2B, panel B). Moreover, mPGES-1/PGE-2 signaling 
was associated to a total loss of NG2 chondroitin sulfate 
proteoglycan staining around the vessels (Supplementary 
Figure S1C, panel A). In contrast, the mPGES-1-/- tumor 
vessels were positive for either NG2 (Supplementary 
Figure S1C, panel B), or α smooth muscle actin (αSMA) 
expression (Figure 2C), indicative of functional vessels 
[15]. In line with the in vitro data, VEGF and HIF-1α were 
over-expressed in mPGES-1+/+ compared to mPGES-1-/- 
tumors (Figure 2D and Supplementary Figure S1D, panel a 
for HIF-1α). Together these results indicate that mPGES-1 
expression is functionally associated with VEGF expression 
and tumor vascularization in DU145 cells. 
mPGes-1/PGe-2 signaling controls mirnA 
expression affecting its maturation
MiRNAs regulate angiogenesis [16, 17]. We 
investigated whether miRNA expression was involved 
in VEGF expression induced by mPGES-1/PGE-2 
signaling in prostate cancer cells. DU145 mPGES-1+/+ and 
mPGES-1-/- cells underwent miRNA expression-profiling 
using miRNA arrays containing 88 human miRNA probes 
(Supplementary Figure S2A). 
We identified a total of 32 miRNAs, 30 of which 
were significantly down-regulated whereas two were up-
regulated in mPGES-1+/+ relative to mPGES-1-/- (> 2.5-fold 
change) (Supplementary Table S1).
Since we postulated that PGE-2 might influence 
the miRNA processing by modulating Drosha or Dicer 
expression, we assessed protein expression of both 
enzymes in tumor cells. In total extract, Drosha protein 
was similar in both cell lines (Figure 3A), its localization 
being confined to the cell nucleus (Supplementary 
Figure S2B, middle lane, DU145 cells). Dicer levels 
were significantly lower in both total (Figure 3A) and 
cytoplasmic extract of mPGES-1+/+ cells (Supplementary 
Figure S2B, DU145 cells) than in mPGES-1-/- cells. 
Dicer expression was undetectable in nuclear extract 
(Supplementary Figure S2B, DU145 cells). Consistently, 
MF63 (10 µM) significantly increased Dicer expression in 
mPGES-1+/+ cells (Figure 3B), whereas exogenous PGE-2 
(1 µM, 2–24 h) decreased in mPGES-1-/- cells (Figure 3C).
As the Dicer promoter has several binding sites 
for AP1 (cJUN+cFOS) and cJUN, we then determined 
the expression of cJUN and cFOS in both tumor 
cells to obtain insights into the mechanism whereby 
mPGES-1/PGE-2 signaling affects Dicer. cJUN and 
cFOS expression was found in the nuclear extract of 
DU145 mPGES-1-/- cells, but was barely detectable 
in mPGES-1+/+ cells (Supplementary Figure S2C). 
Involvement of cJUN and cFOS in inducing Dicer 
expression was further documented by silencing them 
in mPGES-1-/- cells. Knock down of cJUN and/or 
cFOS was sufficient to decrease expression of Dicer in 
mPGES-1-/- (Supplementary Figure S3A). Additional 
evidence of a role of cJUN was obtained by chromatin 
immunoprecipitation assay. In basal conditions (10% 
FBS), cJUN binding to Dicer promoter was greater 
in mPGES-1-/- than in mPGES-1+/+ cells (Figure 3D). 
Exogenous PGE-2 of mPGES-1-/- cells decreased cJUN 
binding to Dicer promoter (Figure 3D). 
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Since cJUN and cFOS also regulate VEGF, we 
evaluated whether their inhibition in mPGES-1-/- cells 
directly affected VEGF expression. cJUN or cFOS 
silencing was not sufficient to reduce VEGF expression 
(Supplementary Figure S3B). Finally, Dicer expression 
was up-regulated relative to mPGES-1+/+ in mouse 
mPGES-1-/- xenografts in vivo (Figure 3E). These results 
suggest that mPGES-1/PGE-2 signaling down-regulates 
cJUN/AP1 and consequently Dicer and miRNA expression 
in prostate cancer cells.
mir-15a and mir-186 controls VeGF expression 
in vitro
Among the miRNAs down-regulated by mPGES-1/
PGE-2 signaling in DU145 cells, some have been involved 
in angiogenesis, others in inflammation or stemness 
(Supplementary Table S1). Five miRNAs (miR-15b, 
miR-93 miR-15a, miR-186 and miR-103) have been 
predicted to target VEGF and HIF-1α on the basis of 
DianaMT, PICTAR5, miRanda, miRBASE, miRWALK 
and Target Scan analysis (Supplementary Table S2). These 
five miRNAs were downregulated in mPGES-1+/+ cells 
(Supplementary Figure S2A). QPCR analysis provided 
further evidence of down-regulation of miR-15a, miR-
186 and miR-103 in mPGES-1+/+ cells (Supplementary 
Figure S4A). miR-15b and miR-93 were not modified.
We also found that treatment of mPGES-1+/+ cells 
with miR-15a, miR-103 or miR-186 mimics (50 nM), 
besides increasing the endogenous pool of their respective 
miRNAs (Supplementary Figure S4B), down-regulated 
VEGF expression/production (p < 0.001, Supplementary 
Figure S4C, S4D, S4E and Figure 4A). The exception was 
miR-103, which failed to affect VEGF (Supplementary 
Figure 1: mPGes-1 increases VeGF expression. (A) Western blot analysis of VEGF and mPGES-1 expression in DU145 and PC3 
mPGES-1+/+ and in mPGES-1-/- cells exposed to 10% FBS (48 h). b-actin was used to normalize loading; N = 3. (b) ELISA for VEGF in 
DU145 and PC3 mPGES-1+/+ and in mPGES-1-/- cells exposed to FBS (1%, 48 h) or to PGE-2 (1 µM, 48 h). DU145 and PC3 mPGES-1-/- 
were obtained by shRNA or CRISP/Cas9 transfection, respectively (see also Materials and Methods for details). ***P < 0.001, **p < 0.01 
vs. mPGES-1-/- cells. (c) VEGF mRNA expression in DU145 and PC3 mPGES-1+/+ and in mPGES-1-/- cells exposed to 10% FBS (48 h). 
Data are reported as fold increase of mPGES-1+/+ vs. mPGES-1-/- cells. ***P < 0.001 vs. mPGES-1-/- cells. (d) VEGF protein expression in 
DU145 and PC3 mPGES-1+/+ exposed to MF63 (10 µM). (e) VEGF protein expression in DU145 and PC3 mPGES-1-/- exposed to PGE-2 
(1 µM). b-actin was used to normalize loading. N = 3. Data expressed in A.D.U. (arbitrary density unit) and as mean ± SD. ***P < 0.001 
vs. untreated cells. 
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Figure S4C, S4D). Conversely, in mPGES-1-/- cells, 
antagomirs for miR-15a and miR-186 (50 nM), which 
decreased the amount of detectable endogenous miR-15a 
or miR-186 (Supplementary Figure S5A), induced VEGF 
expression/production (Supplementary Figure S5B, S5C 
and S5D). Combination of miR-15a and miR-186 mimics 
or antagomirs did not show addictive effects.
To verify the putative direct interaction between 
miR-15a and miR-186 and the VEGF 3′-UTR, the 
3′-UTR-luciferase reporter construct of VEGF and the 
control construct were independently transfected into the 
DU145 and PC3 mPGES-1+/+ cells. The activity of these 
reporters were evaluated in cells mPGEs-1+/+ treated with 
miR-15a, or miR-186 mimics. 
The luciferase assays showed that compared with 
control, miR-15a and miR-186 dramatically decreased 
the luciferase activity of reporter plasmid with the VEGF 
3′UTR. However, miR-15a and miR-186 had no effect on 
luciferase activity of pMir-target vector (Figure 4B). These 
data indicate that VEGF 3′UTR is a specific direct target 
of miR-15a and miR-186. 
Consistently, PGE-2 treatment (1 µM) reversed 
miR-15a and miR-186 expression in mPGES-1-/- cells 
(Supplementary Figure S6A and S6B, DU145 cells), 
corroborating the indication that mPGES-1/PGE-2 
signaling is upstream of miRNAs. Moreover, MF63 
increased levels of both miRs in mPGES-1+/+ cells 
(Figure 4C), and miR-15a and miR-186 were up-regulated 
with respect to mPGES-1+/+ tumors in DU145 mPGES-1-/- 
xenografts in vivo (Figure 4D).
Finally, silencing Dicer in DU145 mPGES-1-/- cells 
promoted VEGF expression/secretion (Figure 5A and 5B) 
and down-regulated miR-15a and miR-186 (Figure 5C), 
indicating that mPGES-1/PGE-2 signaling decreases the 
miR-15a and miR-186/VEGF pathways through inhibition 
of Dicer expression. 
Figure 2: mPGes-1 induces tumor angiogenesis in vivo. (A) Vessel number and size in DU145 and PC3 mPGES-1+/+ and in 
mPGES-1-/- tumors. Quantification of human CD31 and vessel lumen was performed counting ten random fields/sections per slide; each 
slide had five sections. Data represents number of vessels counted per section (left) or vessel diameter (μm) in tumors (right). ***P < 0.001, 
**P < 0.01;*P < 0.05 vs. mPGES-1-/-. (b) Images of vessel perfusion, evaluated by Hoechst 32224 staining (blue), in mPGES-1+/+ (A) or 
mPGES-1-/- tumors (B). Scale bars = 100 μm. Images taken at 10X magnification. (c) Images of double-immunostaining for CD31 (green), 
αSMA (red) and merge in tumor sections from mPGES-1+/+ (top) or mPGES-1-/- group (bottom). Scale bars = 160 μm. Images obtained 
with confocal microscopy at 60X magnification. (d) HIF-1a and VEGF protein expression in tumors from DU145 and PC3 mPGES-1+/+ or 
mPGES-1-/- mice. b-actin was used to normalize loading. N = 3. 
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Figure 3: PGe-2 modulates dicer transcriptional activity. (A) Dicer and Drosha protein expression in total extract from DU145 
and PC3 mPGES-1+/+ and from mPGES-1-/- cells maintained for 18 h in 10% FBS. b-actin was used to normalize loading. N = 3. (b) Dicer 
protein expression in DU145 and PC3 mPGES-1+/+ exposed to MF63 (10 µM). (c) Dicer protein expression in DU145 and PC3 mPGES-1-/- 
exposed to PGE-2 (1 µM). b-actin was used to normalize loading. N = 3. Data expressed in A.D.U. ***P < 0.001, *P < 0.05 vs. untreated 
cells. (d) Analysis of specific binding of AP1 to Dicer promoter region in mPGES-1+/+ and mPGES-1-/- cells by EpiTect Chip qPCR primer 
assay. AP1 transcription factor was immunoprecipitated from cells in basal condition (10% FBS) or from mPGES-1-/- stimulated with PGE-
2 (1 µM). Immunoprecipitated DNA was amplified with specific primers for the Dicer proximal promoter region by QPCR. N = 3. Data is 
expressed as % of input. The % of input of the positive control (chromatin fragments isolated before immunoprecipitation) was 0.83 ± 0.02 
SD. The % of input of the negative control, obtained by immunoprecipitation with normal rabbit serum, was 0.1 ± 0.0 SD. (e) Dicer protein 
expression in tumors from DU145 and PC3 mPGES-1+/+ or mPGES-1-/- mice. b-actin was used to normalize loading. N = 3. 
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mir-186 controls tumor growth and VeGF 
output in vivo
The data presented so far underscores the potential 
link between miR-186 and VEGF/angiogenesis in vivo. 
To test this link, we assayed whether miR-186 inhibiting 
VEGF expression, could reduce angiogenesis and tumor 
size in vivo. miR-186 mimic treatment (3 µg/mouse) of 
DU145 and PC3 mPGES-1+/+ mouse xenograft led to a 
significant reduction in mPGES-1+/+ tumor size compared 
to control tumors (Figure 6A), showed lower vessel 
density and smaller luminal size (Figure 6B left and right 
graph, respectively), as well as a comparable reduction 
in VEGF protein expression (Figure 6C and 6D). This 
indicates that miR-186 is downstream of mPGES-1/PGE-
2 and that it inhibiting VEGF in prostate cancer might 
decrease prostate cancer growth and angiogenesis.
tumor associated-mPGes-1/PGe-2 signaling 
promotes endothelial activation through VeGF 
release
Next we investigated the effect of mPGES-1/
PGE-2 signaling on the activation of endothelial cells 
(a requirement during the angiogenesis process) in vitro 
using a co-culture system with endothelial cells and 
prostate cancer cells. When HUVEC were cultured with 
mPGES-1+/+ tumor cells, plating them in a thin Matrigel 
layer, they organized in a network of cord-like structures 
that invaded the gel (Supplementary Figure S7A, panel 
A). Conversely, when co-cultured with mPGES-1-/- 
cells, the capacity of HUVEC to promote a cord-like 
network was lost (Supplementary Figure S7A, panel 
B vs. A), but restored by pre-treatment with PGE-2 
(Supplementary Figure S7A, panel C vs. panel b, panel 
e for quantification). Evidence of the link between VEGF 
and mPGES-1 signaling was corroborated by experiments 
in which the VEGF neutralizing antibody (bevacizumab) 
added to DU145 mPGES-1+/+-HUVEC co-culture 
(Supplementary Figure S7A panel D) markedly reduced 
cord-like network formation (Supplementary Figure S7A 
panel D vs. panel C, panel e for quantification). These 
results indicate that mPGES-1/PGE-2 signaling induced 
robust activation of endothelial cells controlling the output 
of angiogenic factors in prostate cancer cells. 
In line with the above results we found that 
treatment of DU145 mPGES-1+/+ cells with miR-15a or 
miR-186 mimics (50 nM) reduced the ability of HUVEC 
Figure 4: mPGes-1 down-regulates mir-15a and mir-186 upstream of VeGF expression. (A) ELISA for VEGF in DU145 
and PC3 mPGES-1+/+ cells (1% FBS, 48 h) transfected with miR-15a, miR-186 or miR-103 mimics (50 nM). ***P < 0.001 vs. mPGES-1+/+ 
control cells. (b) Endogenous requirement of miR-15a and miR-186 as VEGF inhibitors. Bars show expression of the VEGF 3′UTR 
reporters in DU145 and PC3 mPGES-1+/+ cells treated with miR-15a and miR-186 mimics. Data are reported as fold increase vs mPGES-1+/+ 
control cells. ***P < 0.001 vs. mPGES-1+/+ control cells. (c) miRNA levels measured by QPCR in DU145 and PC3 mPGES-1+/+ treated 
with MF63 (10 μM, 18 h). ***P < 0.001, *P < 0.05 vs. untreated cells (Ctr). (d) miRNA levels measured by QPCR in tumors from DU145 
mPGES-1+/+ or mPGES-1-/- mice. Data is reported as multiples of increase in expression in mPGES-1+/+ vs. mPGES-1-/- cells (=1). N = 5. 
***P < 0.001 vs. mPGES-1-/- cells.
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to form cord-like structures (Supplementary Figure S7B, 
panel B, C, and D). Conversely, antagomirs for miR-15a 
and miR-186 (50 nM) induced abundant sprouting in 
mPGES-1-/- cells (Supplementary Figure S7C panel B, C, 
and D). Finally, silencing of Dicer in DU145 mPGES-1+/+ 
cells increased HUVEC-mediated sprouting in the co-
cultured model (Supplementary Figure S7D, panel B, and 
C), indicating that mPGES-1/PGE-2 promotes activation 
of endothelial cells in prostate cancer cells by reducing 
Dicer, miR-15a and miR-186 expression, thus promoting 
VEGF secretion. 
expression of mPGes-1 in prostate tumors 
associates with elevated VeGF expression and 
microvessel density
Prostate cancer tissue samples express mPGES-1 
[5]. In order to investigate whether there was an 
association between mPGES-1, Dicer expression and 
VEGF/angiogenesis in these samples we assessed 
expression levels of mPGES-1 with Dicer and angiogenic 
markers (CD31, VEGF and HIF-1α) in human specimens 
with different tumor grade/staging. On histopathologic 
stratification of the tumors, we observed that mPGES-1 
expression was clearly detectable in 21 of the 27 advanced 
cancers (AC) (78%, Supplementary Table S3), but in 
only 7 of the 25 organ-confined (OC) samples (28%, 
Supplementary Table S3). Consistently, in 21 out of 27 
AC samples (78%), VEGF and HIF-1α also appeared 
to be high expressed (Figure 7A and 7B, bottom lane 
for representative images). In the AC samples, low 
expression of Dicer appeared to be associated with high 
expression of mPGES-1, VEGF and HIF-1α (66.7%, 
Figure 7A and 7B, bottom lane for representative images). 
Conversely, 72% of OC samples showed low expression 
of mPGES-1, VEGF and HIF-1α that was associated with 
high expression of Dicer Figure 7A and 7B, top lane for 
representative images). Moreover, when compared to OC 
samples, AC samples showed higher microvessel density 
as indicated by CD31 staining (Figure 7C, p < 0.01). In 
6 OC and 10 AC samples we also investigated miR-15a 
and miR-186 expression. We observed that 66.7 % of OC 
samples expressed significant levels of miR-15a and miR-
186, whereas only 30% and 20% of AC samples expressed 
significant levels of miR-15a and miR-186, respectively 
(Figure 7A). A weak but negative association among miR-
Figure 5: mirnA and VeGF expression/production in dicer silenced mPGes-1-/- cells. (A) Dicer and VEGF protein 
expression in scrambled and in Dicer siRNA-transfected DU145 mPGES-1-/- cells. b-actin was used to normalize loading. N = 3. (b) ELISA 
immunoassay for VEGF in scrambled and in Dicer siRNA-transfected DU145 mPGES-1-/- cells. ***P < 0.001 compared to scrambled cells. 
(c) mRNA levels of mature miRNA measured by QPCR in DU145 mPGES-1-/- cells silenced for Dicer. Results are expressed as multiples 
of increase in miRNA expression in DU145 mPGES-1-/- scrambled vs. Dicer siRNA–transfected cells (=1). **p < 0.01, *p < 0.05 compared 
to Dicer siRNA-transfected mPGES-1-/- cells.
Oncotarget44357www.impactjournals.com/oncotarget
15a or miR-186 and mPGES-1 and VEGF expression in 
OC and AC tissue was noted. These miRNAs therefore 
appear to be elevated in samples with lower levels of 
mPGES-1 and VEGF. Collectively, these results suggest 
miR-15a and miR-186 as potential prognostic biomarkers 
in advanced prostate cancer linking high mPGES-1 levels 
with enhanced VEGF/angiogenic features. 
dIscussIon
These results demonstrate that prostate cancer cells 
constitutively expressing mPGES-1, DU145 cells and PC3 
cells, activate endothelial cells through output of VEGF, 
which was causally linked to PGE-2 production. Although 
the angiogenesis-promoting effect of PGE-2 in tumors 
has been described in a number of reports [2, 18–20], its 
mechanism remains to be elucidated. Here we showed 
that PGE-2  alters tumor miRNA biogenesis, resulting in 
increased VEGF expression and in tumor angiogenesis. 
These observations were gathered in prostate cancer 
cells, in one set of which the mPGES-1 enzyme was 
persistently knocked-down and/or deleted (mPGES-1-/-), 
or pharmacologically inhibited by the specific inhibitor 
MF63, while in a second set, cells were transfected with 
a control shRNA or CRISP/Cas9 plasmid (mPGES-1+/+). 
Evidence of miRNA involvement in mPGES-1/PGE-
2 signaling-promoted tumor angiogenesis was gleaned 
over several experiments. For example: a) sharp 
downregulation of Dicer, cFOS and cJUN expression 
in mPGES-1+/+ cells with respect to mPGES-1-/-, b) 
decreasing angiogenic phenotype in mPGES-1+/+ cells 
after Dicer silencing, or silencing of its promoters (cFOS 
and cJUN); c) reduced binding of cJUN to Dicer in 
mPGES-1+/+, detected by chromatin immunoprecipitation; 
d) increased Dicer expression in mPGES-1+/+ after enzyme 
blockade by MF63.
Insights into the regulatory mechanism of miRNA 
were provided by gene profiling, which revealed that 
32 out of 88 miRNA genes were significantly different 
(change by factor/quotient > 2.5) in mPGES-1+/+ cells, 
thirty and two of which were down- and up-regulated, 
respectively (see green vs. red color in the Supplementary 
Figure S2). Further analysis (QPCR) pointed to three 
miRNAs (miR-15a, -103, and -186). The functional 
relevance of the selected miRNA was demonstrated in 
cultured mPGES-1+/+ cells, where exposure to specific 
Figure 6: mir-186 controls tumor growth and angiogenesis in vivo. (A) Antitumor activity evaluated in nude mice inoculated 
with DU145 and PC3 mPGES-1+/+ and treated subcutaneously with miR186 mimic or negative control. Data is expressed as tumor volume 
(mm3). ***P < 0.001 compared to mPGES-1+/+ treated with negative non-targeting control. Six nude mice per experimental group. (b) 
Vessel number and size in tumors from DU145 or PC3 mPGES-1+/+ treated with control or 186 mimic. Quantification of human CD31 and 
vessel lumen was performed by counting ten random fields/sections per slide; each slide had five sections. Data represents the number of 
vessels counted per section (left) or vessel diameter (μm) in tumors (right). ***p < 0.001, *p < 0.05 vs. control tumors. (c) VEGF protein 
expression in tumors from DU145 or (d) PC3 mPGES-1+/+ treated with control or 186 mimic. β-actin was used to normalize loading. N = 3. 
***P < 0.001 vs. Ctr tumors.
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miRNA synthetic mimics reduced VEGF and impaired 
ability to elicit endothelial cell sprouting. The opposite 
emerged from experiments on mPGES-1-/- cells incubated 
with synthetic antagomirs, where we observed a large 
increase in VEGF output and a rich network of cord-like 
structures of endothelial cells, similar to that obtained after 
exposure to PGE-2. PGE-2 showed a surprising ability 
to reverse the up-regulation of miR-15a and miR-186 in 
mPGES-1-/- cells, which indicates that the effect occurred 
up-stream of the miRNA system. MiR-186 decreased in 
response to PGE-2 in a time dependent manner, while 
miR-15a showed a more complex kinetic, which might 
be associated with the complexity of the system or the 
technical issue [21]. Collectively, this study provides 
clear evidence that the oncogenic drive of prostate cancer 
cells is closely regulated by the expression of miRNAs 
which act by restraining the output of angiocrine factors 
from tumor cells. mPGES-1 plays a pivotal role in miRNA 
expression, as it decreases Dicer expression.
However, controversies on the role of Dicer in tumor 
growth have emerged since in prostate adenocarcinoma, 
increase and decrease of Dicer expression have both been 
reported [22, 23]. Nonetheless, suppressing Dicer activity 
in prostate cancer cells has been shown to reduce growth, 
but to lead to a more invasive phenotype [24]. Another 
caveat concerns the observed magnitude of mPGES-1 
effect in tumor xenografts on VEGF/HIF-1α up-regulation 
and tumor growth, suggesting that other miRNAs than 
miR-15a and -186, downstream to Dicer inhibition, and 
other target than VEGF, might be involved [25–28]. In 
addition, as previously described for miR-15a, deregulated 
miRNAs might also affect stroma cell functions supporting 
tumor progression and angiogenesis [29, 30].  Reduced 
expression of miR-15a has been reported to be associated 
with anti-apoptotic, proliferative, invasive and angiogenic 
properties of cancer cells [31–33]. Other experiments 
comparing mPGES-1+/+ with mPGES-1-/- cells helped 
to define the aggressive traits imparted to tumors by 
mPGES-1. In fact, when mPGES-1+/+ were co-incubated 
with HUVEC (Matrigel assay) we observed enhanced 
output of VEGF and abundant cord-like sprouting that 
specifically regressed with bevacizumab, a VEGF-
neutralizing antibody. Moreover, when these cells were 
implanted in nude mice we detected enhanced VEGF 
and HIF-1α expression, accompanied by significantly 
enhanced tumor growth and vessel density compared to 
mPGES-1-/- cells. An important experiment performed 
on mPGES-1+/+ mouse xenograft models clearly 
showed that sub-chronic treatment with miR-186 mimic 
significantly reduced tumor growth, angiogenesis and 
VEGF expression [34, 35, 36]. Thus, it appears that tumor-
intrinsic mPGES-1 promotes VEGF expression and new 
vessel formation. an harbinger of dissemination favoring 
tumor expansion [19]. The involvement of mPGES-1 in 
prostate cancer progression is in line with observations in 
other tumors and underscores the role of an inflammatory 
milieu in the development of malignancies [5, 18, 20, 
37–39]. Other evidence documents the role of miR-15a 
Figure 7: mPGES-1 expression in human prostate cancers is associated with elevated CD31, VEGF, and HIF-1α 
expression and reduced dicer, mir-15a and -186 expression. (A) Pie charts represent the percentage of expression of mPGES-1, 
VEGF, HIF-1α and Dicer in donors of prostate tissues (OC A and AC B). Black slice represents samples positive for mPGES-1, VEGF and 
HIF-1α and negative for Dicer; grey slice represents samples negative for mPGES-1, VEGF and HIF-1α and positive for Dicer; black slice 
with white dot indicates samples negative for mPGES-1, VEGF, HIF-1α and Dicer; squared slice shows samples positive for mPGES-1, 
VEGF, HIF-1α and Dicer (positive samples are calculated as sum of H-score 1, 2 and 3). (D) Pie charts display tumor grade and miR-15a (A 
and B) and miR-186 (c and d) expression in cancer samples. (b) Immunohistochemical analysis of mPGES-1, VEGF, HIF-1α and Dicer in 
organ-confined prostate cancers (OC) with low Gleason score (top lane) and in locally advanced prostate cancers (AC) with high Gleason 
score (bottom lane). The hematoxylin-eosin stained sections are included as basal control. Scale bars indicate 50 µm, magnification 25X. 
(C) Quantification of human CD31 was performed counting ten random fields/sections per slide; each slide had three sections. *P < 0.05; 
T3 prostate cancer (AC) compared to T2 prostate cancer (OC). 
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and miR-186 as pro-oncogenic molecules [25, 26], as 
clinical studies have observed that reduced expression of 
these miRNAs is associated with poor clinical prognosis in 
prostate cancer, and other tumors [25, 27, 28].
The translational relevance of these results is 
indicated by observations on human prostate cancer 
specimens from a small set of patients undergoing radical 
prostatectomy. The patients were assigned to organ-
confined and advanced prostate cancer groups on the 
basis of PSA level, tumor stage and Gleason score. Given 
the small number of samples no statistical analysis was 
performed. Nonetheless, we recorded higher expression of 
mPGES-1, VEGF and HIF-1α together with lower Dicer 
expression in the advanced group (AC) contrasting with 
low expression of all parameters in the organ-confined 
(OC) group. Sharper differences in vessel density were 
also recorded, with the advanced group showing nearly 
three times the vessel density of the OC group. Moreover, 
high levels of miR-15a and -186 were more frequently 
expressed in organ-confined than in advanced tumor 
samples, demonstrating a direct association between the 
two miRNAs and VEGF expression. 
In conclusion, the results demonstrate that high 
PGE-2 levels reduce Dicer expression and consequently 
miRNA biogenesis in prostate cancer cells. PGE-2-
mediated downregulation of miR-15a and miR-186 is 
specifically related to VEGF production and angiogenesis. 
Considering the influence of miR-15a and miR-186 on 
angiogenesis and VEGF output in prostate cancer cells, 
we suggest that these miRs could be potential candidates 
for attenuating the aggressive traits of prostate cancer. 
This alternative approach might overcome the chemo-




DU145 wild type (WT, passages 5–20, ATCC® 
HTB-81™, certified by STRA, LGC Standards S.r.l., Sesto 
San Giovanni, Milan, Italy) is a prostate cancer cell line 
with high constitutive expression of mPGES-1 [5]. DU145 
mPGES-1 knockdown (mPGES-1-/-, passages 8–20) and 
control cells, transfected with scrambled non-target 
shRNA (mPGES-1+/+, passages 8–20) cells were obtained 
and cultured as described [5]. 
Three different mPGES-1- knockdown clones have 
been used Lenti vector plasmids for mPGES-1 and control 
were obtained from Sigma Aldrich (Supplementary Figure 
S8A). All the plasmids were sequence verified. The 
sequence of plasmid inserted in DU145 cells clone 1 is: 
5′-CCGGGCTGCTGGTCATCAAGATGTACTCGAGTA 
CATCTTGATGACCAGCAGCTTTTTG-3′, the sequence 
of plasmid inserted in DU145 cells clone 2 is: 
5′-CCGGGCTCTGCAGATCCTCTGGGAACTCGAGTT 
CCCAGAGGATCTGCAGAGCTTTTTG-3′. To generate 
mPGES-1 knockdown (-/-) cells, 1 × 106 HEK293 cells 
(Life Technologies) were transfected with 2.25 μg of 
PAX2 packaging plasmid (Addgene, Camb ridge, MA, 
USA), 0.75 μg of PMD2G envelope plasmid (Addgene), 
and 3 μg of pLKO.1 (Addgene) hairpin vector utilizing 
12 μl of Lipofectamine 2000 on 10 cm plates. Polyclonal 
populations of transduced cells were generated by 
infection with 1 MOI (multiplicity of infectious units) of 
lentiviral particles. At 3 days post infection, cells were 
selected with 20 μg/ml neomycin/kanamycin (Sigma 
Aldrich) for 1 week.
Compared to DU145 wild type (WT), transfection of 
cells with the scrambled non-target shRNA (mPGES-1+/+, 
detail in Supplementary data) did not affect mPGES-1/
PGE-2 and VEGF expression/production (Supplementary 
Figure S8B–S8D). Further, differences in the mPGES-1/
PGE-2 expression/secretion did not affect the in vitro 
proliferation rate of these two cell lines (Abs 0.98 ± 0.07 
and 0.91 ± 0.1 for DU145 mPGES-1+/+ and mPGES-1-/- 
cells, respectively, measured by MTT assay). 
PC3 wild type (WT, passages 8-20, ATCC® 
CRL-1435™, certified by STRA) prostate cancer cells 
were from ATCC, Milan, Italy. Cells were grown in 
RPMI 1640 (Sigma Aldrich, St. Louis, MO, USA) 
supplemented with 10% FBS. Gene silencing of 
mPGES-1 in PC3 cells by CRISPR/Cas9 technology 
is reported below (Supplementary Figure S8E). In this 
cell model, mPGES-1 expression slightly increases the 
in vitro proliferation rate: (0.93 ± 0.08 and 0.65 ± 0.3 
for PC3 mPGES-1+/+ and mPGES-1-/- cells, respectively, 
measured by MTT assay). Compared to PC3 wild type 
(WT), transfection of cells with control CRISPR/Cas9 
vector (mPGES-1-+/+) did not affect mPGES-1/PGE-2 and 
VEGF expression/production or in vitro proliferation rate 
(Supplementary Figure S8F–S8H; Abs 0.77 ± 0.03 and 
0.82 ± 0.08 for PC-3 mPGES-1+/+ and mPGES-1-/- cells, 
respectively). 
DU145 and PC3 WT prostate cancer cell lines were 
immediately expanded after delivery (up to 6 × 107 cells) 
and frozen down (1 × 106/vial) such that both cell lines 
could be restarted after a maximum of 10 passages every 
3 months from a frozen vial of the same batch of cells. 
Control of mycoplasma was done from a frozen vial.
Human umbilical vein endothelial cells (HUVEC, 
passages 3–10) were from Lonza, Milan, Italy (C2519A, 
certified for expression of CD31/105, von WFVIII, and 
positivity for acetylated low density lipoprotein uptake). 
Cells were grown in endothelial growth medium (EGM-2) 
(Clonetics, Milan, Italy) supplemented with 10% FBS. All 
cells remained in culture for less than 6 months.
Oncotarget44361www.impactjournals.com/oncotarget
Knockout of PtGes1 gene by crIsPr/cas9-
mediated genome editing 
PC3 cells were transfected with 1.5 μg RNA 
CRISPR plasmids (Santa Cruz, Santa Cruz, CA, USA) 
using Lipofectamine 2000 (Life Technologies, Carlsbad, 
CA, USA) according to the manufacturer›s instructions. 
Beginning the day after transfection, these cells were 
treated with 1 μg/ml of puromycin. Surviving cells were 
reseeded at 1 cell per well in a 96-well plate. Expression 
of mPGES-1 in expanded colonies was detected by 
immunoblotting to select the mPGES-1-depleted colonies. 
Three different mPGES-1-depleted clones have been used.
reagents
Reagents were as follows: PGE-2 (Sigma Aldrich); 
Lipofectamine 2000 (Life technologies); MF63 (AbMole 
Biosciences, Colleretto Giacosa, TO, Italy); DY554 
phalloidin (Thermo Fisher Scientific, Waltham, MA, 
USA), puromycin (Gibco, Thermo Fisher Scientific).
Immunoblot analysis
Total protein lysates were obtained as previously 
described [18]. The following antibodies were used: 
VEGF (Merck Millipore, Darmstadt, Germania), Dicer 
(Abcam, Cambridge), Drosha (Cell Signalling, Danvers, 
MA, USA) all 1:1000, mPGES-1 (1:200, Cayman 
chemicals, Ann Arbor, Mi, USA) or HIF-1α (1:300, BD- 
Transduction Laboratories, Milan, Italy).
nuclear/cytoplasm translocation
To assess translocation of Dicer, Drosha, cJUN and 
cFOS from cytosol to nucleus, 8 × 105 cells were plated 
in 10 cm diameter dishes, maintained in 10% FBS for 
18 h and then scraped, homogenized on ice in a lysis 
buffer containing (in mM) 10 HEPES, 1 DTT, 10 KCl, 
50 NaF, 0.1 EDTA, 0.1 EGTA, 1 Na3VO4, 0.5 PMSF and 
0.1 NP-40 at 4°C, and centrifuged at 1000 g for 10 min 
to separate the nuclei. The supernatant was centrifuged 
at 13,200 g for 5 min to yield the cytosolic fraction. The 
nuclear fraction was lysed in buffer containing (in mM) 
20 HEPES, 1 EDTA, 1 EGTA and 0.5 PMSF and analysed 
for cFOS (Merck Millipore), Dicer (Abcam), Drosha 
and cJUN (Cell Signaling), all 1:1000. Western blot was 
performed as described [18]. Images were digitized with 
the program CHEMI DOC Quantity One, blots were 
analyzed in triplicate by densitometry using NIH Image 
1.60B5 software, and the results in arbitrary densitometric 
units (A.D.U.) were normalized for β-actin, β-tubulin or 
lamin (Sigma Aldrich).
VeGF immuno-assays 
VEGF was determined in supernatant using a 
Quantikine kit (R&D System, Milan, Italy). 3 × 104 cells 
were exposed to 10% FBS or to PGE-2 (1 μM) for 48 h or 
siRNA-transfected for Dicer or transfected with mimics 
for miR-15a, miR-186, miR-103 or with miRNA inhibitors 
for miR-15a and miR-186. The conditioned media were 
collected, diluted in the standard diluents, and assayed as 
indicated in manufacturer’s instructions.
QPcr
Total RNA was obtained using an RNA mini kit 
(Qiagen, Inc., Milan, Italy). RNA (0.5 µg) was reverse 
transcribed using a RT-PCR kit (Applied Biosystems, 
Foster City, USA). Used as an internal control, GAPDH 
was assessed using premixed reagents from Applied 
Biosystems. VEGF mRNA detection was measured 
using the optimized TaqMan assay-on-demand (Applied 
Biosystems) and GAPDH detection was performed 
using TaqMan Universal PCR Master Mix (Applied 
Biosystems). The results were expressed as fold increase 
-ΔCt. miRNA expression was measured by QPCR according 
to the manufacturer’s instructions (miScript Primer Assay, 
Qiagen) and the results are expressed as multiples of 
increase or 2^-ΔCt. The mature miRNA sequences used are 
listed in Supplementary Table S2.
Assay of luciferase activity
3′UTR of VEGF-A construct and pMir-Target 
Vector were obtained from Origene (Rockville, MD;USA) 
and used according to the manufacturer’s instructions 
protocol Cells were harvested 48 h after co-transfection 
of miRNA mimics with reporter vector and assayed with 
Dual Luciferase Assay (Promega, Milan, Italy) according 
to the manufacturer’s instructions protocol. 
In vitro endothelial cell sprouting 
Tube formation assay was assessed as described 
[40]. For detail see supplementary data. 
sirnA/mirnA transfection 
The siRNAs sequences: human cJUN 
(5`-AAGAACGTGACAGATGAGCAG-3′) and human 
cFOS (5′- AACCTGCTGAAGGAGAAGGAA-3′), were 
from Qiagen. The day before transfection, cells were 
trypsinized, and 2 × 105 cells were seeded in 6-well plates. 
Transient transfection of siRNA was carried out using 
Lipofectamine 2000 (Life Technologies) according to the 
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manufacturer’s instructions. Cells were assayed 48 h after 
transfection. 
The miRNA mimics and inhibitors for miR-
103, miR-186 and miR-15a were from Qiagen and 
transfection was performed with Lipofectamine 2000 (Life 
Technologies) following the manufacturer’s protocol. 
Oligonucleotides were used at a final concentration of 
50 nM in antibiotic-free opti-modified Eagle’s medium 
(Life Technologies). miRNA levels were validated by 
QPCR. Conditioned media and cell extracts were prepared 
for analysis 48 h after transfection.
Expression of 88 mature human miRNAs in DU145 
cells was profiled using QPCR (miFinder, Sabiosciences, 
Qiagen). Gene expression data was normalized to SNORD 
44, SNORD 47 and SNORD 48. RNU6-2, miRTC and 
PPC were controls for the array. Relative expression was 
determined for each of the 88 miRNAs using the formula 
2^-ΔCt. 
To assess differential miRNA expression in 
scrambled, Dicer siRNA-transfected DU145 mPGES-1-/- 
cells, we isolated total RNA using miRNeasy Mini 
kit (Qiagen). miRNA expression was measured by 
QPCR according to the manufacturer’s instructions 
(miScript Primer Assay, Qiagen). Gene expression 
data was normalized to SNORD 48. The mature 
miRNA sequences used are listed in Supplementary 
Table S2. miRNA mimics and inhibitors target the 
following mature miRNA sequences: for miR-186-5p 
(5′-CAAAGAAUUCUCCUUUUGGGCU-3′), for miR-
15a-5p (5′-UAGCAGCACAUAAUGGUUUGUG-3′) 
and for miR-103-3p (5′-AGCAGCAUUGUACAGGGCU 
AUGA-3′).
mirnA expression analysis
For determination of global baseline miRNA 
expression, total RNA was isolated from tumor cells using 
miRNeasy Mini kit (Qiagen). 
chromatin immunoprecipitation assay
Chromatin immunoprecipitation assays were 
performed as previously described [41]. Experimental 
details are reported in supplementary data.
tumor xenograft
Experiments have been performed in accordance 
with the EEC guidelines for animal care and welfare 
(EEC Law No. 86/609) and National Ethical Committee. 
As recommended by EEC guidelines and Italian National 
laws for animal experimentation, to investigate the role of 
miR-15a and miR-186 mimics and inhibitors on VEGF 
expression and growth of DU145 and PC3 xenografts, we 
minimized the number of animals focusing on miR-186 
mimic. The experiments were approved from Italian Health 
Ministry, d.m. n° (215/2011-B). Samples were obtained as 
previously described [18]. Details are in supplementary data.
human Pca specimen analysis 
Radical prostatectomy specimens were collected 
from the University Hospital of Florence after written 
informed consent to perform this analysis was obtained 
from all patients. The hematoxylin-eosin stained sections 
were reviewed to confirm the diagnosis. Twenty-five 
carcinomas were limited to the prostate (OC, pT2) and were 
moderately differentiated (Gleason score = 6), whereas 
27 cases were non-organ-confined (locally advanced 
PCa, AC, pT3/pT4) with a high Gleason score (≥ 7). 
Patients’ median age was 69 years (range 41–80 years).
Representative formalin-fixed, paraffin-embedded 
tumor tissue blocks were selected and 4-µm sections 
for each lesion were prepared for immunohistochemical 
analysis. Antigen retrieval was performed for 20 min 
in citrate buffer (pH 6.6) in a microwave at 500 W for 
VEGF, mPGES-1, HIF-1α and Dicer, and for 30 min 
in TRIS buffer (pH 9) in a microwave at 500 W for 
CD31. The sections were then allowed to cool down to 
room temperature for 20 minutes. After inactivating 
endogenous peroxidase activity and blocking cross-
reactivity with 3% BSA, the slides were incubated at 4°C 
for 18 h with a dilute solution of mPGES-1 (1:50, Thermo 
Scientific), VEGF (1:100, Merck Millipore), CD31 (1:50, 
Dako, Cernusco sul Naviglio, MI, Italy), Dicer (1:100, 
Santa Cruz, Santa Cruz, CA, USA) and HIF-1α (1:100, 
Thermo Scientific). Location of primary antibodies was 
achieved by subsequent application of biotin-conjugated 
anti-primary antibody, streptavidin-peroxidase and 
diaminobenzidine (Sigma Aldrich). The staining was 
developed using a commercial immunoperoxidase staining 
kit following the manufacturer’s instructions (biotin-
streptavidin complex method, Merck Millipore). The 
slides were counterstained with hematoxylin. 
Immunohistochemical staining was interpreted by 
two experienced pathologists without knowledge of the 
clinical data associated with each specimen. An H-score 
was calculated by using intensity (score of 3: strongly 
staining; score of 2: moderately staining; score of 1: 
weakly staining; score of 0: no staining) × percentage 
of tumor tissue stained (score of 1: 0–25%; score of 2: 
26–50%, score of 3: 51–75%; score of 4: 76–100%) for 
each case.
Purification of total RNA, including miRNA, 
from FFPe tissue sections
Formalin-fixed, paraffin-embedded sections (10 μm 
thick) of human prostate cancer were deparaffinized 
with deparaffinization solution (Qiagen) and purified 




Immunohistological analysis was performed 
as previously described [18]. Experimental details of 
immunohistological staining of tumor tissues are reported 
in supplementary data.
statistical analysis
Results are expressed as means ± SD. Statistical 
analysis was carried out using using Student t test when 
appropriate and Bonferroni test (GraphPad) for multiple 
comparison. P < 0.05 was considered statistically 
significant.
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